1. A method of treating an inflammatory disease or disorder in a subject in which a PKCα, PKCε or PKCη inhibitor is administered to the subject and thereby treating the inflammatory disease or disorder in the subject. The method of claim 1, wherein the inhibitor is a polypeptide having a length of from 5 to 20 amino acids. The method according to claim 2, where the polypeptide contains an amino acid sequence selected from SEQ ID NO: 1-5, 14-19, 26, 27 and their physiologically acceptable salts, as well as from SEQ ID NO: 6-13, 20, 21, 28 and 29.4. The method of claim 3, wherein the polypeptide comprises an N-terminal modification, a C-terminal modification, or a combination thereof. The method of claim 4, wherein the polypeptide is N-acylated, namely N-myristoylated or N-palmitoylated. The method of claim 2, wherein the polypeptide is administered parenterally, subcutaneously, intravenously, topically, orally, through the mucosa, rectally, pulmonary, nasal or through the ear. The method of claim 2, wherein the polypeptide is administered at a dose of from about 0.1 to about 10,000 micrograms per kilogram. The method of claim 2, wherein the polypeptide is administered daily, weekly, every two weeks, or monthly. The method of claim 1, wherein the inflammatory disease or disorder is selected from the group consisting of psoriasis, multiple sclerosis, rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto thyroiditis, severe myasthenia gravis, type 1 and type 2 diabetes, asthma, inflammatory lung disease, inflammatory lesion liver, inflammatory glomerular lesions, atopic dermatitis, allergic contact dermatitis, contact dermatitis, seborrheic dermatitis, Sjogren's syndrome, keratoconjunctivitis, uveitis, inflammatory bowel disease, pain Crohn's knowledge, ulcerative colitis, inflate�1. Способ лечения воспалительного заболевания или расстройства у субъекта, при котором вводят субъекту ингибитор РКСα, PKCε или РКСη и таким образом лечат воспалительно
